We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+20.97%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$2.51B
AUM Growth
+$287M
Cap. Flow
+$70.5M
Cap. Flow %
2.8%
Top 10 Hldgs %
85.06%
Holding
41
New
2
Increased
6
Reduced
3
Closed
2

Top Buys

Rank Stock Value
1
CRSP icon
CRISPR Therapeutics
CRSP
+$60.2M
2
RARX
Ra Pharmaceuticals, Inc. Common Stock
RARX
+$47.5M
3
SBBP
Strongbridge Biopharma plc.
SBBP
+$8.15M
4
TCON
TRACON Pharmaceuticals, Inc. Common Stock
TCON
+$4.97M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$4.89M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$33.8M
2
NVRO
NEVRO CORP.
NVRO
+$25.7M
3
XCOM
XTERA COMMUNICATIONS INC COM STK (DE)
XCOM
+$2M
4
HIVE
Aerohive Networks
HIVE
+$43.8K
5
CASC
Cascadian Therapeutics, Inc.
CASC
+$6

Sector Composition

Rank Sector Weight
1 Healthcare 87.32%
2 Communication Services 2.65%
3 Technology 1.25%
4 Consumer Discretionary 1.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TSRO
1
DELISTED
TESARO, Inc.
TSRO
$1.38B 54.94%
10,275,113
– –
ARDX icon
2
Ardelyx
ARDX
$1.25B
$200M 7.95%
14,083,582
– –
DERM
3
DELISTED
Dermira, Inc.
DERM
$106M 4.23%
3,506,649
– –
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$75.8M 3.01%
6,260,851
– –
SENS icon
5
Senseonics Holdings Inc
SENS
$260M
$70.2M 2.79%
1,315,264
+105
+0% +$6K
AKAO
6
DELISTED
Achaogen Inc
AKAO
$67.9M 2.7%
5,215,125
+499,997
+11% +$3.43M
GRPN icon
7
Groupon
GRPN
$1.08B
$66.7M 2.65%
1,003,788
– –
CRSP icon
8
CRISPR Therapeutics
CRSP
$4.71B
$65.3M 2.59%
+3,220,728
New +$60.2M
RARX
9
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$53.1M 2.11%
+3,493,636
New +$47.5M
CBIO
10
Crescent Biopharma
CBIO
$563M
$52.4M 2.08%
85,841
– –
CLVS
11
DELISTED
Clovis Oncology, Inc.
CLVS
$50.6M 2.01%
1,139,890
– –
KA
12
DELISTED
Kineta, Inc. Common Stock
KA
$43.6M 1.73%
25,406
– –
ADAP
13
DELISTED
Adaptimmune Therapeutics
ADAP
$40M 1.59%
9,880,999
– –
LXRX icon
14
Lexicon Pharmaceuticals
LXRX
$1.03B
$32.9M 1.31%
2,382,286
– –
CRCM
15
DELISTED
CARE.COM, INC.
CRCM
$27.9M 1.11%
3,260,989
– –
HIVE
16
DELISTED
Aerohive Networks
HIVE
$26.6M 1.06%
4,673,536
-7,919
-0.2% -$43.8K
NVRO
17
DELISTED
NEVRO CORP.
NVRO
$26.1M 1.04%
359,678
-300,750
-46% -$25.7M
TRVN
18
DELISTED
Trevena, Inc.
TRVN
$22.4M 0.89%
6,099
– –
ELGX
19
DELISTED
Endologix Inc
ELGX
$14.2M 0.57%
249,020
– –
TCON
20
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$13.5M 0.54%
13,796
+4,348
+46% +$4.97M
SBBP
21
DELISTED
Strongbridge Biopharma plc.
SBBP
$9.94M 0.4%
4,141,308
+2,000,000
+93% +$8.15M
AUPH icon
22
Aurinia Pharmaceuticals
AUPH
$1.95B
$8.54M 0.34%
4,067,743
+1,520,900
+60% +$4.89M
CASC
23
DELISTED
Cascadian Therapeutics, Inc.
CASC
$7.72M 0.31%
1,791,666
-1
-0% -$6
RIGL icon
24
Rigel Pharmaceuticals
RIGL
$733M
$7.72M 0.31%
324,315
– –
AVEO
25
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$5.6M 0.22%
1,036,269
– –
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
KOCAA
Knights of Columbus Asset Advisors New Haven, Connecticut $1.77B AUM 31.28% 1-Year Est. Return

NEA Management Company's Q4 2016 Portfolio in Review

As of Q4 2016, NEA Management Company held 41 positions worth $2.51B, up 13% from $2.23B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

NEA Management Company's Q4 2016 filing shows 2 new, 6 increased, 3 reduced and 2 closed positions. Its largest new stake was CRISPR Therapeutics: 3,220,728 shares worth $65.3M. The largest sale was Loxo Oncology, Inc, an estimated $33.8M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 84% a quarter earlier, followed by Communication Services and Technology.

  • NEA Management Company's largest Q4 2016 buy was CRISPR Therapeutics: 3,220,728 shares worth $65.3M.
  • NEA Management Company added most to Strongbridge Biopharma plc. in Q4 2016, an estimated $8.15M increase.
  • NEA Management Company's biggest Q4 2016 reduction was NEVRO CORP., cutting an estimated $25.7M.
  • NEA Management Company fully exited Loxo Oncology, Inc in Q4 2016, selling an estimated $33.8M.
  • NEA Management Company's ten largest holdings make up 85% of its $2.51B portfolio in Q4 2016.
  • NEA Management Company opened 2 new positions and closed 2 in Q4 2016.
  • NEA Management Company's portfolio value rose 13% quarter-over-quarter to $2.51B.

Based on NEA Management Company's 13F filing for Q4 2016, filed 9 Feb 2017.